A Phase 1 interventional study of REGN4461 and Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-09.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the safety and tolerability of REGN4461 in healthy participants. The secondary objectives of the study are to:
This is a 2-part study of the safety, tolerability, PK and pharmacodynamic (PD) of single and repeated doses of REGN4461 in healthy participants. In Part A, healthy lean or overweight participants will be enrolled to evaluate the safety, tolerability, PK, and PD of single ascending intravenous (IV) and subcutaneous (SC) doses. Interim PK and safety information from Part A will be used to select the dose level, frequency, and mode of administration (IV or SC) for repeat dosing in Part B. In Part B, overweight/obese participants with body mass index (BMI) 25-40 kg/m2 will be enrolled to evaluate the safety, tolerability, PK, and PD of repeated doses of REGN4461 in 4 distinct cohorts defined by baseline leptin levels.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
Part A:
Part B:
Key Exclusion Criteria
Part A:
Part B:
Key Exclusion Criteria (Parts A and B):
Note: Other inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
Drug: REGN4461 · Drug: Placebo
REGN4461
Placebo-matching REGN4461
Number of treatment-emergent adverse events (TEAEs)
Time frame: Up to week 27
Concentrations of REGN4461 in serum over time
Time frame: Up to week 27
Percent change from baseline to week 12 in body weight in overweight or obese participants
Time frame: Baseline to week 12
Absolute change from baseline to week 12 in body weight in overweight or obese participants
Time frame: Baseline to week 12
Change from baseline in caloric intake in response to standardized meals in overweight or obese participants
Time frame: Baseline to week 12
Change in lipid-regulating protein levels over time after single doses of REGN4461
Time frame: Up to week 16
Change in lipid-regulating protein levels over time after repeated doses of REGN4461
Time frame: Up to week 27
Incidence of anti-drug antibodies to REGN4461 over time after single doses of REGN4461
Time frame: Up to week 16
Incidence of anti-drug antibodies to REGN4461 over time after repeated doses of REGN4461
Time frame: Up to week 27
Pharmacokinetic (PK) parameter: Area under curve (AUC) computed from time zero to the time of the last positive concentration (AUClast)
Time frame: Up to week 27
PK parameter: AUC computed across a dosing interval with length τ (AUCo-τ)
Time frame: Upt to week 27
PK parameter: peak concentration (Cmax)
Time frame: Up to week 27
PK parameter: time to Cmax (tmax)
Time frame: Up to week 27
PK parameter: clearance (CL)
Time frame: Up to week 27
PK parameter: trough concentration (Ctrough)
Time frame: Up to week 27
Ran from Apr 2018 to primary completion in Jan 2020, 21 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mibavademab